0825 Ovid
BioCentury & Getty Images

Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

Aug 26, 2020 | 2:10 AM GMT

Ovid and Takeda are zeroing in on Dravet syndrome patients for a Phase III trial of soticlestat after Phase II data showed the therapy fared better in the smaller indication than it did in Lennox-Gastaut syndrome.

The readout places

Read the full 566 word article

How to gain access

Continue reading with a
two-week free trial.